Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Biotechnology

Healthcare
$2.82 -1.97%

-$0.24 today

Market cap
$54.80M
Beta
1.68
P/E (TTM)
-1.1
EPS (TTM)
-$10.75
52W Low $10.03High $69.97

Volume 1.04M

Average 0.49M

TNXP Income Before Tax

Profit after all operating and non-operating items but before income tax.

Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$40.19M, compared with -$16.83M a year earlier. Trailing-twelve-month income before tax was -$147.39M.

Context

  • Income before tax amounted to 946.2% of revenue in FY2025, down 342.0 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$40.19M or moves back toward the trailing-twelve-month quarterly average of -$36.85M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$40.19M+14.3% QoQ
Last fiscal yearDec 2025
-$124.02M+4.6% YoY
LTMMar 2026
-$147.39M-11.7% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-138.8%——
1 year+4.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(124.02M) USD
Year-over-year change
+4.6%

Income Before Tax vs competitors

How TNXP compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -11.7% is the 6th highest of 10, against a peer median of +0.6%.
  • Income before tax amounts to 839.5% of revenue for TNXP, versus a peer median of 3842.2%.
TNXP Competitors
Income Before Tax for TNXP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$40.19M USD+21.6%——
MCRBSeres Therapeutics, Inc.LTM Mar 2026-$46.9M USD+22.1%—4088.8%
IPHAInnate Pharma S.A.FY2025-€49.18M EUR+0.6%—1764.5%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$68.55M USD-32.0%—3842.2%
FBRXForte Biosciences, Inc.LTM Mar 2026-$74.45M USD-70.3%——
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026-$78.11M USD-319.6%——
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$84.57M USD-215.6%—143340.7%
NKTXNkarta, Inc.LTM Mar 2026-$99.93M USD+10.2%——
FATEFate Therapeutics, Inc.LTM Mar 2026-$129.91M USD+26.1%—2056.8%
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026-$147.39M USD-11.7%—839.5%
Peer median (excluding TNXP) —+0.6%—3842.2%

Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue007.77M10.09M13.11M
Cost of Revenue004.74M7.77M8.57M
Gross Profit003.03M2.33M4.54M
Gross Margin——39.0%23.1%34.7%
Research & Development68.84M81.88M86.66M40.45M44.49M
Selling, General & Admin23.47M30.22M34.75M40.1M85.76M
Operating Expenses92.31M112.09M121.41M139.03M130.25M
Depreciation & Amortization50K1.25M4.29M3.42M1.93M
EBITDA(92.24M)(108.97M)(112.37M)(74.32M)(122.01M)
EBITDA Margin——-1446.5%-736.3%-930.9%
Operating Income(92.31M)(112.09M)(118.38M)(136.7M)(125.7M)
Operating Margin——-1523.9%-1354.3%-959.1%
Interest Income25K1.87M004.15M
Interest Expense000089K
Other Income / Expenses25K1.87M1.72M6.67M1.68M
Income Before Tax(92.29M)(110.22M)(116.66M)(130.04M)(124.02M)
Pre-Tax Margin——-1501.8%-1288.3%-946.2%
Income Tax Expense00000
Net Income(92.29M)(110.22M)(116.66M)(130.04M)(124.02M)
Net Margin——-1501.8%-1288.3%-946.2%
EPS (Basic)(163,968.00)(811.68)(6,368.84)(176.60)(14.57)
EPS (Diluted)(163,968.00)(811.68)(6,368.84)(176.60)(14.57)
Weighted Avg Shares5633.07M1.83M2.26M8.51M
Weighted Avg Shares (Diluted)5633.07M1.83M2.26M8.51M

Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Intrinsic Alpha fair value

Locked

Current Price

$2.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.